Roche (RHHBY) announced that the European Commission (EC) approved PiaSky (crovalimab) for treating patients suffering from paroxysmal nocturnal hemoglobinuria (PNH).PiaSky is a novel recycling monoclonal antibody that inhibits the complement protein C5. Per Roche, the drug is the first monthly subcutaneous (SC) treatment for people with PNH.The EC approved the drug for adults and adolescents (12 years of age or older with a weight of 40 kg and above) suffering from PNH who are either new to or have been pr ...